Dr Lisa McKerracher has been appointed CEO of privately held Emerillon Therapeutics Inc. McKerracher joined the Montreal-based company last August to refocus its multiple technologies toward product development and clinical trials. She has been a professor at both McGill Univ and the Univ of Montreal and left academic research to become the founding scientist and chief scientific officer of BioAxone Therapeutic. Emerillon is a biotechnology firm focused on infectious disease and plans to move at least one compound toward clinical trials in the near term….